Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by M.D. Anderson Cancer Center
Sponsor:
Collaborators:
Novartis
Onyx Therapeutics, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01301807
First received: February 21, 2011
Last updated: June 30, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)